Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:20:36.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria 6' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' which includes examples such as a person's general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now specifies detailed inclusion and exclusion criteria for participants, such as having histologically confirmed melanoma and unresectable Stage III or IV melanoma per AJCC staging system.
    Difference
    37%
    Check dated 2024-05-22T20:26:16.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:15:59.000Z thumbnail image

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.